Avita Medical Ltd (RCEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avita Medical Ltd (RCEL) has a cash flow conversion efficiency ratio of 0.327x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.44 Million) by net assets ($-16.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Avita Medical Ltd - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Avita Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Avita Medical Ltd (RCEL) total liabilities for a breakdown of total debt and financial obligations.
Avita Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avita Medical Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dong Phu Rubber JSC
VN:DPR
|
0.048x |
|
Bioversys AG
SW:BIOV
|
N/A |
|
Maple Gold Mines Ltd
V:MGM
|
-0.062x |
|
Cheffelo AB
ST:CHEF
|
0.097x |
|
GeoVision Inc
TW:3356
|
0.024x |
|
Master Drilling Group Ltd
JSE:MDI
|
0.027x |
|
EcoSynthetix Inc
TO:ECO
|
0.014x |
|
Affinity Bancshares Inc
NASDAQ:AFBI
|
0.018x |
Annual Cash Flow Conversion Efficiency for Avita Medical Ltd (1993–2025)
The table below shows the annual cash flow conversion efficiency of Avita Medical Ltd from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Avita Medical Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-16.65 Million | $-31.20 Million | 1.874x | +117.22% |
| 2024-12-31 | $4.50 Million | $-48.94 Million | -10.878x | -1303.85% |
| 2023-12-31 | $49.06 Million | $-38.01 Million | -0.775x | -243.95% |
| 2022-12-31 | $84.74 Million | $-19.09 Million | -0.225x | -30.67% |
| 2021-12-31 | $104.62 Million | $-18.04 Million | -0.172x | +45.13% |
| 2020-12-31 | $72.40 Million | $-22.75 Million | -0.314x | +66.00% |
| 2019-12-31 | $20.83 Million | $-19.25 Million | -0.924x | -83.92% |
| 2017-12-31 | $18.99 Million | $-9.54 Million | -0.502x | +60.87% |
| 2016-12-31 | $5.12 Million | $-6.58 Million | -1.284x | -48.41% |
| 2015-12-31 | $6.85 Million | $-5.93 Million | -0.865x | +25.13% |
| 2014-12-31 | $4.22 Million | $-4.87 Million | -1.155x | +1.84% |
| 2013-12-31 | $5.53 Million | $-6.51 Million | -1.177x | -83.67% |
| 2012-12-31 | $10.46 Million | $-6.70 Million | -0.641x | -27.02% |
| 2011-12-31 | $8.55 Million | $-4.32 Million | -0.505x | -174.05% |
| 2010-12-31 | $16.99 Million | $-3.13 Million | -0.184x | +46.35% |
| 2009-12-31 | $3.98 Million | $-1.36 Million | -0.343x | +36.51% |
| 2008-12-31 | $6.93 Million | $-3.75 Million | -0.541x | -97.65% |
| 2007-12-31 | $12.96 Million | $-3.54 Million | -0.273x | +60.53% |
| 2006-12-31 | $10.98 Million | $-7.60 Million | -0.693x | -6.46% |
| 2005-12-31 | $11.15 Million | $-7.26 Million | -0.651x | -69.41% |
| 2004-12-31 | $13.09 Million | $-5.03 Million | -0.384x | +21.56% |
| 2003-12-31 | $8.66 Million | $-4.24 Million | -0.490x | -304.84% |
| 2002-12-31 | $8.25 Million | $-997.61K | -0.121x | -67.46% |
| 2001-12-31 | $4.53 Million | $-327.44K | -0.072x | +16.82% |
| 2000-12-31 | $5.38 Million | $-467.41K | -0.087x | +42.40% |
| 1999-12-31 | $2.72 Million | $-409.81K | -0.151x | -0.12% |
| 1998-12-31 | $1.10 Million | $-166.28K | -0.151x | -24.15% |
| 1997-12-31 | $1.78 Million | $-215.74K | -0.121x | -16.34% |
| 1996-12-31 | $4.98 Million | $-519.14K | -0.104x | -17.25% |
| 1995-12-31 | $4.48 Million | $-398.66K | -0.089x | +9.97% |
| 1994-12-31 | $5.82 Million | $-574.61K | -0.099x | -2049.66% |
| 1993-12-31 | $6.55 Million | $33.17K | 0.005x | -- |
About Avita Medical Ltd
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitili… Read more